Mark Schneider, Nestlé CEO (Ludovic Marin/Pool via AP Images)

Nestlé parts with peanut al­ler­gy treat­ment Pal­forzia

Peanut al­ler­gies proved a tough nut to crack for Nestlé, which an­nounced Mon­day it has di­vest­ed its treat­ment Pal­forzia to Swiss al­ler­gy spe­cial­ist Stal­ler­genes Greer.

Nestlé ac­quired Pal­forzia in its $2.6 bil­lion takeover of Aim­mune in 2020, months af­ter the peanut pow­der pill be­came the first FDA-ap­proved treat­ment for peanut al­ler­gy. The idea is to grad­u­al­ly ex­pose pa­tients to small but in­creas­ing amounts of the al­ler­gen to build re­sis­tance. Nestlé had high hopes for Pal­forzia, but CEO Mark Schnei­der said on an in­vestor call in No­vem­ber that it end­ed up be­ing more of a “niche ther­a­py” than a block­buster.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.